Viking Therapeutics completes patient enrolment in VANQUISH-2 trial

Viking Therapeutics has completed enrolment in its Phase III VANQUISH-2 trial of subcutaneous VK2735, enrolling about 1,000 adults with type 2 diabetes and obesity; the 78-week, randomised study will compare three dose levels with placebo and uses percent change in body weight at 78 weeks as the primary endpoint.

Viking Therapeutics said it has completed patient enrolment in the Phase III VANQUISH-2 trial of VK2735. The study evaluates subcutaneous VK2735, a dual GLP-1 and GIP receptor agonist, in adults with type 2 diabetes who are obese or overweight. About 1,000 participants were enrolled across multiple centres. The trial is randomised, double-blind and placebo-controlled with a main dosing period of 78 weeks. Key facts: - Enrolment included around 1,000 adults with type 2 diabetes who had a BMI of at least 30 kg/m² or who were overweight with a BMI of at least 27 kg/m². - Participants were randomised to weekly subcutaneous VK2735 at 7.5 mg, 12.5 mg or 17.5 mg, or to placebo, for 78 weeks. - The primary endpoint is percent change in body weight from baseline at 78 weeks versus placebo. - Secondary and exploratory endpoints include the proportions of patients achieving at least 5%, 10%, 15% and 20% body weight reduction. - A 52-week extension period allows ongoing treatment following the main dosing phase. - Viking completed enrolment in the Phase III VANQUISH-1 trial in November 2025 and said it expects to complete the VANQUISH studies in 2027. Summary: The completion of enrolment allows the study to proceed through its dosing and follow-up periods to assess weight outcomes at the 78-week primary time point. Viking described VANQUISH-2 as the second of two registration studies to be fully enrolled and indicated plans to complete the VANQUISH programme in 2027. Further timing for primary readouts was not provided.